CL2011002100A1 - Composicion farmaceutica que comprende (4ar,10ar)-1-n-propil-1,2,3,4,4a,5,10,10a-octahidro-benzo[g]quinolin-6,7-diol y sus derivados, para administracion por mucosa oral, nasal o a traves de la piel; y su uso para el tratamiento de la enfermedad de parkinson. - Google Patents

Composicion farmaceutica que comprende (4ar,10ar)-1-n-propil-1,2,3,4,4a,5,10,10a-octahidro-benzo[g]quinolin-6,7-diol y sus derivados, para administracion por mucosa oral, nasal o a traves de la piel; y su uso para el tratamiento de la enfermedad de parkinson.

Info

Publication number
CL2011002100A1
CL2011002100A1 CL2011002100A CL2011002100A CL2011002100A1 CL 2011002100 A1 CL2011002100 A1 CL 2011002100A1 CL 2011002100 A CL2011002100 A CL 2011002100A CL 2011002100 A CL2011002100 A CL 2011002100A CL 2011002100 A1 CL2011002100 A1 CL 2011002100A1
Authority
CL
Chile
Prior art keywords
octahydro
quinolin
parkinson
benzo
nasal
Prior art date
Application number
CL2011002100A
Other languages
English (en)
Inventor
Hakan Wikstrom
Morten Mork Niels Larsen Jennifer Jorgensen
Andersen Benny Sager Thomas Nikolaj Puschl Ask To Bang
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42102075&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011002100(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of CL2011002100A1 publication Critical patent/CL2011002100A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composición farmacéutica que comprende (4ar,10ar)-1-n-propil-1,2,3,4,4a,5,10,10a-octahidro-benzo[g]quinolin-6,7-diol y sus derivados, para administración por mucosa oral, nasal o a través de la piel; y su uso para el tratamiento de la enfermedad de Parkinson.
CL2011002100A 2009-02-27 2011-08-26 Composicion farmaceutica que comprende (4ar,10ar)-1-n-propil-1,2,3,4,4a,5,10,10a-octahidro-benzo[g]quinolin-6,7-diol y sus derivados, para administracion por mucosa oral, nasal o a traves de la piel; y su uso para el tratamiento de la enfermedad de parkinson. CL2011002100A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200900274 2009-02-27
DKPA200900282 2009-02-27
DKPA200900279 2009-02-27

Publications (1)

Publication Number Publication Date
CL2011002100A1 true CL2011002100A1 (es) 2012-06-22

Family

ID=42102075

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002100A CL2011002100A1 (es) 2009-02-27 2011-08-26 Composicion farmaceutica que comprende (4ar,10ar)-1-n-propil-1,2,3,4,4a,5,10,10a-octahidro-benzo[g]quinolin-6,7-diol y sus derivados, para administracion por mucosa oral, nasal o a traves de la piel; y su uso para el tratamiento de la enfermedad de parkinson.

Country Status (17)

Country Link
US (1) US20120077836A1 (es)
EP (1) EP2400955A1 (es)
JP (1) JP2012519156A (es)
KR (1) KR20110138213A (es)
CN (1) CN102333524A (es)
AR (1) AR075626A1 (es)
AU (1) AU2010217058A1 (es)
BR (1) BRPI1006953A2 (es)
CA (1) CA2751321A1 (es)
CL (1) CL2011002100A1 (es)
CO (1) CO6410283A2 (es)
EA (1) EA201171087A1 (es)
IL (1) IL213501A0 (es)
MX (1) MX2011008627A (es)
SG (1) SG174164A1 (es)
TW (1) TW201035054A (es)
WO (1) WO2010097091A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015009796A1 (en) * 2013-07-17 2015-01-22 Dow Global Technologies Llc Composition for application to a mucosa comprising a methylcellulose
BR112019014981A2 (pt) 2017-11-24 2020-04-07 H Lundbeck As composto, sal farmaceuticamente aceitável, uso dos mesmos e composição farmacêutica
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
JP7562562B2 (ja) * 2019-05-21 2024-10-07 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1303684B1 (it) * 1998-10-30 2001-02-23 Chiesi Farma Spa Formulazioni di apomorfina in soluzione stabili nel tempo.
US6765001B2 (en) * 2001-12-21 2004-07-20 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteroid delivery
TWI404702B (zh) * 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥

Also Published As

Publication number Publication date
EP2400955A1 (en) 2012-01-04
JP2012519156A (ja) 2012-08-23
AU2010217058A1 (en) 2011-09-08
BRPI1006953A2 (pt) 2016-04-26
CO6410283A2 (es) 2012-03-30
KR20110138213A (ko) 2011-12-26
SG174164A1 (en) 2011-10-28
MX2011008627A (es) 2011-09-06
IL213501A0 (en) 2011-07-31
AR075626A1 (es) 2011-04-20
TW201035054A (en) 2010-10-01
WO2010097091A1 (en) 2010-09-02
US20120077836A1 (en) 2012-03-29
EA201171087A1 (ru) 2012-02-28
CA2751321A1 (en) 2010-09-02
CN102333524A (zh) 2012-01-25

Similar Documents

Publication Publication Date Title
CL2011002100A1 (es) Composicion farmaceutica que comprende (4ar,10ar)-1-n-propil-1,2,3,4,4a,5,10,10a-octahidro-benzo[g]quinolin-6,7-diol y sus derivados, para administracion por mucosa oral, nasal o a traves de la piel; y su uso para el tratamiento de la enfermedad de parkinson.
ECSP11011235A (es) Dicianopiridinas alquilamino-sustituidas y sus profármacos de éster de aminoácido
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
SV2010003581A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
ECSP099452A (es) Derivados de éster y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides
UY31228A1 (es) Ariloxazoles sustituidos y su uso
GT200900095A (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hermatologicas.
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
UY32970A (es) Acidos 3-fenilpropionicos sustituidos y su uso
CR10489A (es) Derivados fenil-pirazol como ligandos de receptores glucocorticoides no esteroides
NI200800207A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina
SV2009003098A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
UY29079A1 (es) Acidos fenoxiacéticos sustituidos, composiciones que los contienen, procedimientos de preparación y aplicaciones
CO6300954A2 (es) Derivados de tienopiridinonas como activadores de proteina quinasa activados por ampk
ECSP088414A (es) Derivados de ácido bifeniloxiacético para el tratamiento de una enfermedad respiratoria
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CO6771409A2 (es) Acidos 1-bencilcicloalquilcarboxilicos sustituidos y su uso
UY29223A1 (es) Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación
CR10243A (es) "bencimidazoles 2-sustituidos como modulares de receptor de androgeno selectivos"
GT200600109A (es) Derivados de acido pirimidincarboxilico y su uso
AR060880A1 (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
PA8784101A1 (es) Oxazolidinonas sustituidas y su uso
AR054129A1 (es) Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7
UY31310A1 (es) Ácidos 6-fenilnicotínicos sustituidos y su uso